Lymphoepithelioma-like carcinoma of the breast

Nankin, Nils L.; Gondusky, Christina J.; Abasolo, Peter A.; Kalantari, Babak N.

doi:10.2484/rcr.v10i1.963

Cited by 7 publications

(6 citation statements)

References 13 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, a patient with LELC of the breast had a profound response to docetaxel, doxorubicin, and cyclophosphamide and incorporation of chemotherapy with surgery and radiation has yielded complete, durable responses in head and neck LELC patients. 14,15 The use of ICIs in the treatment paradigm of LEL-HCC has not been previously described. One case report describes a 37 year-old woman with pulmonary LELC who was treated with nivolumab after progressive disease on systemic chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Checkpoint Inhibition in the Treatment of Unresectable, Advanced Lymphoepithelioma-like Hepatocellular Carcinoma

Hermel¹,

Du²,

Lin³

et al. 2021

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

Lymphoepithelioma-like hepatocellular carcinoma (LEL-HCC) is a very rare neoplasm, with distinct epidemiologic, morphologic and clinical characteristics. Molecular mechanistic insight into the pathogenesis of this carcinoma suggests a pivotal role for the host immune system in the proliferation and progression of this tumor. However, while detailed genomic profiling of these hepatic tumors have revealed an intra-tumoral inflammatory mutational signature that may predispose to immune checkpoint inhibitor efficacy, no published report has described their use in this tumor type. Unfortunately, with near 100 cases of LEL-HCC reported in the literature to date and the majority of cases confined to localized and resectable disease, current evidencebased practices in the unresectable setting are lacking, with unknown benefit of chemotherapy or immunotherapy. We report on the case of a 68 year-old man with unresectable, advanced LEL-HCC who had evidence of disease stability after starting on the immune checkpoint inhibitor nivolumab. His disease response persisted off therapy for over a year and was potentially augmented by radiotherapy at the site of local progression. For this extremely rare tumor subtype, this case highlights the potential efficacy and safety of immune checkpoint blockade in LEL-HCC and reinforces the need for more robust, large-scale analysis of patients with these rare tumors to better evaluate treatment strategies and outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Checkpoint Inhibition in the Treatment of Unresectable, Advanced Lymphoepithelioma-like Hepatocellular Carcinoma

Hermel¹,

Du²,

Lin³

et al. 2021

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

show abstract

“…In the lung and nasopharynx, it has been associated with Epstein-Barr virus, and human papillomavirus leading to squamous cell carcinomas with lymphoid elements [3].…”

Section: Introductionmentioning

confidence: 99%

Lymphoepithelial Carcinoma of the Breast

Arora,

Balasubramanian,

Mohammad Kamel Aljasem

et al. 2023

Cureus

View full text Add to dashboard Cite

Lymphoepithelial malignancy is an extremely rare carcinoma of the breast characterized by a confusing histopathological picture resembling medullary carcinomas, lymphoma, etc. It has also been reported in other regions of the body like salivary glands, nasopharyngeal area and sometimes the lung. Due to its rare presence and difficult diagnosis, the treatment is often prolonged and delayed.Here we present a case report of a 56-year-old lady who was eventually diagnosed as lymphoepithelial carcinoma of the breast. Her journey of evaluation and treatment was fraught with pathological nuances and an elimination drill of multiple differentials before concluding this rare diagnosis. Although lymphoepithelial-like carcinoma is a rare entity, multiple cases have been reported in the literature and their review is mandated to further our clinical knowledge about the oncological treatment and expected prognosis of such cases in the future. Our patient underwent a simple mastectomy, followed by chemotherapy, radiotherapy, and is completely asymptomatic now. She has been cancer-free for the last seven years so far.

show abstract

“…Lymphoepithelioma-like carcinoma (LELC) is a poorly differentiated carcinoma occurring outside the nasopharynx, which displays identical histological features to its nasopharyngeal counterpart. It has been reported in several anatomic sites including breast [3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25], colon [26], esophagus [27], kidney [28], lacrimal gland [29,30], larynx [31], hepatobiliary system [32,33], lungs [34], major and minor salivary glands [35,36,37,38], orbital adnexa [39], prostate [28], skin [40], stomach [41], thymus [42], thyroid [43], trachea [44], ureter [45], urinary bladder [46], uterine cervix [47], vagina [48], and vulva…”

Section: Introductionmentioning

confidence: 99%

“…Due to the rarity of this entity no solid evidence regarding the optimal treatment strategy exists. Patients with LELC-B are excluded from randomised controlled trials, and their management is therefore based on anecdotal cases or published case reports [23].…”

Section: Introductionmentioning

confidence: 99%

Lymphoepithelioma-like breast carcinoma

Koufopoulos¹,

Syrios²,

Papanikolaou³

et al. 2018

pjp

View full text Add to dashboard Cite

Nasopharyngeal lymphoepithelioma is an undifferentiated carcinoma in a dominated lymphoplasma-histiocyte stroma. Lymphoepithelioma-like carcinoma of the breast is the mammary counterpart of the lymphoepithelioma of the nasopharynx and is characterised by proliferation of poorly differentiated malignant cells within a prominent lymphoid infiltrate. It is a very rare primary carcinoma of the breast first reported in 1994 by Kumar and Kumar. Fewer than 40 cases have been reported in the English literature. In this manuscript a case of lymphoepithelioma-like carcinoma of the breast in a 57-year-old patient is reported along with a literature review on this rare entity.

show abstract

Lymphoepithelioma-like carcinoma of the breast

Cited by 7 publications

References 13 publications

Checkpoint Inhibition in the Treatment of Unresectable, Advanced Lymphoepithelioma-like Hepatocellular Carcinoma

Checkpoint Inhibition in the Treatment of Unresectable, Advanced Lymphoepithelioma-like Hepatocellular Carcinoma

Lymphoepithelial Carcinoma of the Breast

Lymphoepithelioma-like breast carcinoma

Contact Info

Product

Resources

About